3 reports of this reaction
4.6% of all LYCOPODIUM CLAVATUM SPORE reports
#1 most reported adverse reaction
DIZZINESS is the #1 most commonly reported adverse reaction for LYCOPODIUM CLAVATUM SPORE. There are 3 FDA adverse event reports linking LYCOPODIUM CLAVATUM SPORE to DIZZINESS. This represents approximately 4.6% of all 65 adverse event reports for this drug.
Patients taking LYCOPODIUM CLAVATUM SPORE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is moderately reported among LYCOPODIUM CLAVATUM SPORE users, representing a notable but not dominant share of adverse events.
In addition to dizziness, the following adverse reactions have been reported for LYCOPODIUM CLAVATUM SPORE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 3 FDA reports for LYCOPODIUM CLAVATUM SPORE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 4.6% of all adverse event reports for LYCOPODIUM CLAVATUM SPORE, making it one of the most commonly reported side effect.
If you experience dizziness while taking LYCOPODIUM CLAVATUM SPORE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.